Gilead That Gave the World the Toxic Useless COVID-19 Drug Remdesivir is Laying Off Staff
Nikhil Prasad Fact checked by:Thailand Medical News Team Dec 10, 2024 1 day, 13 hours, 28 minutes ago
Pharma News: Biotech giant Gilead Sciences, once hailed for its pharmaceutical advancements, is now in the spotlight for a different reason: significant layoffs and office closures. Known globally for its contributions to HIV treatment and its controversial COVID-19 drug, Remdesivir, the California-based company has announced plans to cut over 100 positions at its Foster City headquarters.
Gilead That Gave the World the Toxic Useless COVID-19 Drug Remdesivir is Laying Off Staff
The announcement, made through a California Worker Adjustment and Retraining Notification (WARN) alert, outlines layoffs involving senior-level executives, including five vice presidents and a senior vice president, alongside directors and other employees in departments such as public affairs, risk governance, and human resources. These cuts are slated to begin in March 2025.
This
Pharma News report explores the broader implications of Gilead’s restructuring, which is part of its strategic plan to align resources for six potential product launches by 2030, starting with a promising HIV prevention drug, lenacapavir, in 2025.
Corporate Realignment
Despite its financial stability - Gilead reported US$7.5 billion in revenue last quarter and remains valued at approximately US$110 billion - the company is shifting gears to streamline operations. This move follows smaller workforce reductions in recent years.
In late 2022, Gilead reduced its workforce by 41 employees at its headquarters. Earlier in April 2023, another 58 positions were eliminated. This trend culminates in the current announcement of 104 layoffs in Foster City and the closure of its sole Seattle facility, affecting 72 employees.
According to company spokesperson Blair Baumwell, the decision reflects Gilead's long-term goals. “Our business is performing well, and our clinical momentum continues to accelerate. However, we are prioritizing resources and aligning them with strategic objectives, which includes relocating some teams and closing offices,” she stated.
Seattle and Philadelphia Operations Affected
The Seattle facility, which focused on research and clinical development, will shut down in early 2025. Affected employees have been offered opportunities to work remotely, apply for other roles within the company, or use severance and job placement services.
Similarly, Gilead plans to wind down operations at its Kite Pharma subsidiary’s Philadelphia site by mid-2025. Kite Pharma specializes in cell therapy, an area Gilead entered through its acquisition of the company in 2017.
These closures signal a shift in Gilead’s operational focus, likely aimed at consolidating resources to support its pipeline of upcoming drug launches.
Controversial Legacy of Remdesivir
While Gilead is widely respected for its contributions to HIV treatment, its COVID-19 antiviral drug, Remdesivir,
has faced intense criticism. Initially touted as a breakthrough treatment for the virus, it was later scrutinized for its limited efficacy and potential toxicity. Many have questioned whether the drug’s development and deployment were rushed, a controversy that has somewhat overshadowed the company’s achievements in other areas.
This shadow looms over Gilead's current challenges, with skeptics pointing to the layoffs as indicative of larger systemic issues within the company.
Future Prospects
Despite the recent workforce reductions, Gilead appears optimistic about its future. The company is investing in innovation, focusing on HIV prevention, hepatitis treatments, and oncology. The upcoming launch of lenacapavir is particularly noteworthy, as it could significantly improve HIV prevention strategies.
However,
Thailand Medical News would like to add that there is a lot of details of the possible adverse effects and also long-term detrimental effects of lenacapavir that has not been disclosed nor explored. We will be doing a series of articles on these soon.
Gilead’s pipeline includes promising advancements in cancer therapy and other critical areas of medicine. If these projects succeed, they could reinforce the company’s reputation as a leader in biopharmaceuticals, offsetting the controversies tied to Remdesivir and the current restructuring.
Conclusion
Gilead Sciences is at a crossroads. While its financial performance and clinical developments remain strong, the recent layoffs and office closures highlight the challenges of navigating a competitive and evolving pharmaceutical landscape. The company’s focus on aligning resources for long-term strategic goals could pave the way for groundbreaking treatments, but it also underscores the human cost of corporate restructuring.
For the employees affected by these changes, the road ahead will undoubtedly be difficult. However, Gilead’s commitment to severance support and job placement services offers some consolation. As the company moves forward, it will need to balance innovation with corporate responsibility to maintain its standing in the industry.
For the latest
Pharma News, keep on logging to Thailand Medical News.
Read Also:
https://www.thailandmedical.news/news/study-finds-that-u-s-fda-s-approved-remdesivir-is-hepatoxic
https://www.thailandmedical.news/news/breaking-japanese-study-finds-u-s-fda-approved-and-promoted-covid-19-drug-remdesivir-induces-cardiomyocyte-dysfunction-and-is-cardiotoxic
https://www.thailandmedical.news/news/molnupiravir--what-wrong-with-america-why-is-the-american-government-and-agencies-funding-and-pushing-potentially-toxic-drugs-to-treat-covid-19
https://www.thailandmedical.news/news/covid-19-drugs-study-published-in-journal-of-the-heart-rhythm-society-warns-that-remdesivir-can-cause-dangerously-low-heart-rate-in-covid-19-patients
https://www.thailandmedical.news/news/covid-19-drugs-university-of-cincinnati-study-warns-against-use-of-u-s-fda-approved-remdesivir-due-to-drug-interactions-and-increased-toxicity
https://www.thailandmedical.news/news/covid-19-antivirals-interim-who-solidarity-trial-results-confirms-that-remdesivir,-lopinavir-and-interferon-have-no-effect-on-covid-19-mortality
https://www.thailandmedical.news/news/covid-19-scams-who-issues-warning-against-use-of-remdesivir-for-covid-19--countries-should-beware-of-any-therapeutics-approved-in-the-usa
https://www.thailandmedical.news/news/america-latest-trump-s-controlled-fda-approves-remdesivir-despite-who-and-other-studies-showing-ineffectiveness-in-treating-covid-19
https://www.thailandmedical.news/news/latest-who-s-solidarity-drug-trial-shows-that-remdesivir-is-not-the-least-effective-in-treating-covid-19
https://www.thailandmedical.news/news/remdesivir-researchers-with-vested-interest-release-final-trial-report-saying-that-remdesivir-is-effective-and-well-tolerated-while-in-europe-regulato
https://www.thailandmedical.news/news/breaking-covid-19-drugs-remdesivir-approved-by-trumps-administration-causes-serious-kidney-problems-eu-regulators-starts-safety-review
https://www.thailandmedical.news/news/must-read-covid-19-drugs-study-shows-that-remdesivir-not-effective-to-treat-moderate-covid-19-patients
https://www.thailandmedical.news/news/breaking-remdesivir-and-covid-19-more-medical-experts-doubting-effectiveness-of-remdesivir-and-voicing-their-concerns-in-new-bmj-report
https://www.thailandmedical.news/news/must-read-covid-19-scandals-more-medical-experts-criticize-claim-that-remdesivir-cuts-death-rates-or-hospitalization-stays
https://www.thailandmedical.news/news/remdesivir-gilead-wants-more-profits-initiates-clinical-trial-of-inhaled-remdesivir-for-less-severe-covid-19-with-hopes-that-trump-admin-will-support-
https://www.thailandmedical.news/news/covid-19-controversies-researchers-from-establishment-famed-for-fraud-and-deceit-publishes-study-showing-that-remdesivir-has-efficacy-against-sars-c
https://www.thailandmedical.news/news/generic-remdesivir-while-americans-have-to-pay-up-to-us$3120-for-gilead%E2%80%99s-remdesivir,-price-war-in-india-has-led-prices-dropping-to-below-us$50
https://www.thailandmedical.news/news/breaking-remdesivir-gilead-sets-price-at-us$2,340-to-us$3,120-for-drug-that-has-no-safety-studies-or-true-efficacy-except-that-it-shortens-hospitaliza
https://www.thailandmedical.news/news/breaking-covid-19-drugs-gilead%E2%80%99s-experimental-drug-remdesivir-fails-in-china%E2%80%99s-clinical-trials
https://www.thailandmedical.news/news/united-states-covid-19-crisis-most-mismanaged-country-in-the-world,-now-dr-fauci-peddling-remdesivir-with-more-lies--1-06-million-americans-tested-pos
Share
Tweet
Share
